BioSpace News Archive

Diadem SpA presented clinical data at the 15th Clinical Trials on Alzheimer’s Disease conference highlighting the accuracy and clinical utility of its AlzoSure® Predict prognostic blood test for Alzheimer’s Disease, setting the stage for commercialization in the U.S. beginning in 2023.

Vicore Pharma Holding AB, a pioneer in the development of angiotensin II type 2 receptor agonists, launched the pivotal phase of COMPANION, the first clinical investigation of a digital cognitive behavioral therapy for patients with pulmonary fibrosis.

Ellipses Pharma Limited will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm in advanced breast cancer at the San Antonio Breast Cancer Symposium in San Antonio, Texas on Tuesday, 6 December from 5:00pm to 6:15pm CST.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for Travelan®.

HilleVax, Inc. (Nasdaq: HLVX) today reported results from a prespecified immunogenicity analysis of the 203 subjects enrolled in the run-in cohort of NEST-IN1 (Norovirus Efficacy and Safety Trial for INfants), the company’s ongoing Phase 2b trial for HIL-214, its investigational virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants.

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Mycapssa® in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide.

BioRestorative Therapies, Inc.(“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Boston Children’s Hospital to study TNX-15001 for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in animals.

Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).